Semaglutide drives weight loss by mimicking glucagon-like peptide-1 (GLP-1), a natural gut hormone that signals fullness to the brain and slows the rate at which food leaves the stomach. By activating GLP-1 receptors in the hypothalamus and brainstem, semaglutide reduces appetite, lowers food cravings, and helps people eat less without conscious calorie counting. The cumulative effect, sustained over months of weekly injections, can produce average weight loss of around 15 percent of body weight at the maximum approved dose.
The Role of GLP-1 in Appetite Regulation
GLP-1 is an incretin hormone secreted by the L-cells of the small intestine when food enters the gut. In its natural form, GLP-1 has a half-life of just a few minutes because it is rapidly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide is a long-acting GLP-1 analog: structural changes to the natural peptide protect it from DPP-4 degradation and allow it to bind to albumin, extending the half-life to approximately one week. That is why a single subcutaneous injection lasts seven days. When GLP-1 receptors in the hypothalamus and brainstem are activated, the brain perceives a stronger satiety signal, and food intake decreases.
How Semaglutide Promotes Weight Loss: The Four Mechanisms
1. Slowed Gastric Emptying
Semaglutide slows the rate at which the stomach empties food into the small intestine. The result is a longer-lasting sense of fullness after meals, smaller portions before reaching satiety, and reduced snacking between meals. This effect is most pronounced in the first weeks of therapy and contributes to the early-onset nausea many users experience.
2. Central Appetite Suppression
GLP-1 receptors are present in the arcuate nucleus of the hypothalamus and in the area postrema of the brainstem. When activated by semaglutide, these regions send fullness signals and reduce hunger drive. Many users report that food simply becomes less interesting, often described as “food noise” turning down. This central effect appears to be the dominant driver of long-term weight loss.
3. Improved Glucose-Dependent Insulin Secretion
Semaglutide enhances insulin release from pancreatic beta cells, but only when blood glucose is elevated. This glucose-dependent action lowers post-meal blood sugar without producing the hypoglycemia that sulfonylureas can cause. Stable glucose levels contribute to fewer hunger swings and less reactive eating, an indirect benefit for weight management.
4. Reduced Glucagon Secretion
By suppressing glucagon release from pancreatic alpha cells when glucose is high, semaglutide reduces hepatic glucose output. This contributes to better fasting glucose control and improved insulin sensitivity over time.
What the STEP Trials Showed
The STEP (Semaglutide Treatment Effect in People with Obesity) program is the foundation for Wegovy’s FDA approval. STEP-1, published in the New England Journal of Medicine, enrolled 1,961 adults with a BMI of 30 or higher (or 27 or higher with a weight-related comorbidity) and without type 2 diabetes. Participants received 2.4 mg subcutaneous semaglutide weekly or placebo, both with lifestyle counseling, for 68 weeks. Mean change in body weight was minus 14.9 percent on semaglutide versus minus 2.4 percent on placebo. Approximately 86 percent of semaglutide participants lost 5 percent or more of body weight, and about one-third lost 20 percent or more.
| STEP Trial | Population | Mean Weight Loss (Semaglutide 2.4 mg) |
|---|---|---|
| STEP-1 | Adults with obesity, no diabetes | Approximately 14.9 percent at 68 weeks |
| STEP-2 | Adults with obesity and type 2 diabetes | Approximately 9.6 percent at 68 weeks |
| STEP-3 | Obesity plus intensive behavioral therapy | Approximately 16.0 percent at 68 weeks |
| STEP-4 | Continued vs withdrawn after week 20 | Continued group lost more; withdrawn group regained |
| STEP-5 | Adults with obesity, 2-year extension | Approximately 15.2 percent at 104 weeks |
Approved Doses for Weight Loss
The Wegovy starting dose is 0.25 mg subcutaneously once weekly, escalated every four weeks (0.5, 1.0, 1.7, 2.4 mg) to a maintenance dose of 2.4 mg weekly. The slow titration is designed to reduce gastrointestinal side effects. Per the Wegovy prescribing information, the medication is intended for use with a reduced-calorie diet and increased physical activity. In 2024, the FDA expanded the Wegovy label to include cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity.
What to Expect Week by Week
- Weeks 1 to 4 (0.25 mg): Mild nausea, slight appetite reduction, minimal weight change. The starting dose is for tolerance, not weight loss.
- Weeks 5 to 16 (0.5 to 1.7 mg): Appetite reduction becomes noticeable. Weight loss of 4 to 8 percent is typical by week 16.
- Weeks 17 to 68 (2.4 mg maintenance): Steady weight loss continues, often plateauing around week 60 at the average loss reported in STEP-1.
- Beyond 68 weeks: Maintenance phase; continued therapy is needed to preserve weight loss, per STEP-4 data.
Side Effects and Serious Warnings
Common side effects, mostly gastrointestinal, include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite. Most are dose-related and improve with slow titration. Less common but serious risks include acute pancreatitis, gallbladder disease (cholelithiasis and cholecystitis), acute kidney injury from dehydration, hypoglycemia in patients also taking insulin or sulfonylureas, severe hypersensitivity reactions, diabetic retinopathy complications, and acute injury related to suicidal behavior or ideation that should be monitored. The label carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
How Lifestyle Choices Amplify Results
Semaglutide reduces calorie intake but does not substitute for diet quality, protein adequacy, or resistance training. Adequate protein (often 1.2 to 1.6 g/kg of goal body weight per day) helps preserve lean mass during rapid weight loss. Resistance training two to three times per week supports lean mass and metabolic rate. The CDC’s obesity prevention resources outline broader behavioral strategies. For prediabetes context and how A1C may improve alongside weight loss, see our pages on treatment options and A1C levels.
The Bottom Line
Semaglutide works for weight loss by hijacking the body’s natural satiety system. It slows gastric emptying, reduces appetite through brain receptors, improves insulin secretion, and lowers glucagon. These effects compound over months of weekly injections to deliver approximately 15 percent average weight loss at the 2.4 mg dose. Results are best when paired with a reduced-calorie diet and physical activity, and weight regain is common if the medication is stopped. Talk with your clinician about whether semaglutide is appropriate for your medical history and goals.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan.
